<DOC>
	<DOCNO>NCT01698697</DOCNO>
	<brief_summary>This trial conduct Africa . The aim trial determine new formulation ( U200 ) insulin aspart contain 200 U/mL bioequivalent market insulin aspart formulation ( U100 ) .</brief_summary>
	<brief_title>Comparison Two Insulin Aspart Formulations Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Normal finding medical history physical examination unless investigator considers abnormality clinically irrelevant Normal laboratory value , electrocardiogram ( ECG ) , vital sign unless investigator considers abnormality clinically irrelevant Body mass index ( BMI ) 1826 kg/m^2 ( inclusive ) Weight 6090 kg Nonsmoker Any condition require regular use medication Known suspect allergy trial product relate product Family history type 1 diabetes mellitus</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>